### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization

International Bureau



## . 1988 E BULLOU I DE BULLO GERU ERIN ERIN ERIN ERIN BERUK ERIN BERUK ERIN BERUK ERIN BERUK ERIN BERUK ERIN BER

(43) International Publication Date 4 November 2004 (04.11.2004)

**PCT** 

# (10) International Publication Number WO 2004/094419 A1

(51) International Patent Classification<sup>7</sup>: 403/14, A61K 31/4375, 31/519
(21) International Application Number:

: PCT/IB2004/001283

C07D 471/04,

(22) International Filing Date:

8 April 2004 (08.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0308208.8 60/485,322 9 April 2003 (09.04.2003) GB 7 July 2003 (07.07.2003) US

- (71) Applicants (for all designated States except US): SB PHARMCO PUERTO RICO INC [US/US]; CSC, The United States Corporation Company, 105 Ponce de Leon Avenue, One Comptroller Plaza, Hato Rey, 00917 (US). NEUROCRINE BIOSCIENCES INC [US/US]; 10555 Science Center Drive, San Diego, California 00917 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): ST-DENIS, Yves [CA/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).
- (74) Agent: GIDDINGS, Peter John; GlaxoSmithKline, Corporate Intellectual Property, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## (54) Title: CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS



(57) Abstract: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, =NR3R4i cyano, and or a group Z; R, is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR3R4or cyano; D, G is -C- optionally substituted; A is -C- optionally substituted; X is carbon or-nitrogen; Y is nitrogen or -C- optionally substituted; W is a 4-8 carbocyclic membered ring, which

may be saturated or may contain one to three double bonds,, and inwhich: - one carbon atom is replaced by a carbonyl or  $S(O)_m$ ; and - one to four carbon atoms may optionally be replaced by oxygen, nitrogen or  $NR_{14}$ ,  $S(O)_m$ , carbonyl, and such ring may be further substituted by I to 8 substituents; Z is a 5-6 membered heterocycle or a phenyl, which may be substituted by I to 8 substituents; m is an integer from 0 to 2, to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).